Clinical trial • Phase I/II|Phase II • Cardiology

Argon; Oxygen for Cardiac arrest

Phase I/II|Phase II trial of Argon; Oxygen for Cardiac arrest.

Overview

Trial Therapeutic Area
Cardiology
Trial Disease
Cardiac arrest
Trial Stage
Phase I/II|Phase II
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
10-09-2024
First CTIS Authorization Date
07-10-2024

Trial design

Randomised, open-label, control-standard: ventilation with a fio2 of 30% (air/o2 standard ventilation) continued for 4 hours (product listed as oxygen). Phase I/II|Phase II trial across 11 sites in Italy.

Randomised
Yes
Open Label
Yes
Comparator
Control-standard: ventilation with a FiO2 of 30% (Air/O2 standard ventilation) continued for 4 hours (product listed as OXYGEN).
Target Sample Size
120
Trial Duration For Participant
180

Eligibility

Recruits 120 adults.

Pregnancy Exclusion
pregnancy

Inclusion criteria

  • {"criterion_text":"- witnessed non-traumatic OHCA of presumably cardiac etiology with a presenting shockable rhythm"}
  • {"criterion_text":"- age ≥ 18 years"}
  • {"criterion_text":"- unconsciousness after return of spontaneous circulation (ROSC)"}
  • {"criterion_text":"- duration of CPR ≤ 40 mins"}
  • {"criterion_text":"- Initiation of study intervention ≤ 4 hrs from ROSC"}
  • {"criterion_text":"- stable SaO2 ≥ 94% (according to the physician’s criteria), with a FiO2 of 30%"}

Exclusion criteria

  • {"criterion_text":"- age < 18 years"}
  • {"criterion_text":"- initiation of the study intervention > 4 hrs from ROSC"}
  • {"criterion_text":"- participation to another clinical trial"}
  • {"criterion_text":"- non-witnessed CA"}
  • {"criterion_text":"- CA of traumatic origin"}
  • {"criterion_text":"- non-presumably cardiac cause"}
  • {"criterion_text":"- non-shockable presenting rhythm (pulseless electrical activity and asystole)"}
  • {"criterion_text":"- women of childbearing potential defined as younger of 50 years"}
  • {"criterion_text":"- pregnancy"}
  • {"criterion_text":"- known terminal illness"}
  • {"criterion_text":"- pre-CA cerebral performance category (CPC) ≥ 3"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- 48 h Serum Neuron Specific Enolase (NSE) concentration for evaluation of Ar activity on neuronal preservation.","definition_or_measurement_approach":"Serum Neuron Specific Enolase (NSE) concentration measured at 48 hours after ROSC."}

Secondary endpoints

  • {"endpoint_text":"- hs-cTnT plasma concentration for evaluation of Ar activity on myocardial preservation;","definition_or_measurement_approach":"High-sensitivity cardiac troponin T (hs-cTnT) plasma concentration measurements to evaluate myocardial preservation."}
  • {"endpoint_text":"- Brain imaging (MRI with DWI and DTI, in patients that remain comatose), for evaluation of Ar activity on neuronal preservation;","definition_or_measurement_approach":"Brain MRI including DWI and DTI sequences in patients who remain comatose to assess neuronal preservation."}
  • {"endpoint_text":"- Multiorgan function (circulating biomarkers);","definition_or_measurement_approach":"Assessment of multiorgan function via circulating biomarkers (unspecified biomarkers as per protocol)."}
  • {"endpoint_text":"- Survival and CPC score up to 6 months, for evaluation of functional outcome.","definition_or_measurement_approach":"Survival status and Cerebral Performance Category (CPC) score assessed up to 6 months post-ROSC."}

Recruitment

Planned Sample Size
120
Recruitment Window Months
46

Geography

Total Number Of Sites
11
Total Number Of Participants
120

Italy

Earliest CTIS Part Ii Submission Date
29-07-2024
Latest Decision Or Authorization Date
16-03-2026
Processing Time Days
595
Number Of Sites
11
Number Of Participants
120

Sites

Site Name
IRCSS Ospedale Policlinico San Martino
Department Name
Anestesia e Rianimazione
Contact Person Name
Chiara Robba
Contact Person Email
chiara.robba@unige.it
Site Name
Ospedale Santa Chiara
Department Name
Rianimazione Generale, Anestesia e Rianimazione 1,
Contact Person Name
Alberto Cucino
Contact Person Email
alberto.cucino@apss.tn.it
Site Name
Azienda Ospedaliero Universitaria Delle Marche
Department Name
SOD Clinica di Anestesia e Rianimazione Generale, Respiratoria e del Trauma Maggiore
Contact Person Name
Abele Donati
Contact Person Email
a.donati@staff.univpm.it
Site Name
Azienda Ospedaliera Friuli Occidentale, ASFO Pordenone
Department Name
SC Anestesia e Rianimazione
Contact Person Name
Tommaso Pellis
Contact Person Email
thomas.pellis@gmail.com
Site Name
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Department Name
Dipartimento di Scienze dell'Emergenza, Anestesiologiche e della Rianimazione
Contact Person Name
Claudio Sandroni
Contact Person Email
Claudio.Sandroni@unicatt.it
Site Name
Ospedale Maggiore Carlo Alberto Pizzardi – AUSL Bologna, Bologna (IT)
Department Name
UOC Rianimazione ed Emergenza Territoriale 118 –
Contact Person Name
Lorenzo Gamberini
Site Name
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
Department Name
UOC Anestesia e Terapia Intensiva Adulti
Contact Person Name
Giuseppe Ristagno
Site Name
Azienda Ospedaliero - Universitaria di Parma
Department Name
Struttura Complessa Terapia Intensiva Anestesia e Rianimazione
Contact Person Name
Edoardo Picetti
Contact Person Email
edoardopicetti@hotmail.com
Site Name
Arcispedale S. Maria Nuova in Reggio Emilia
Department Name
Rianimazione
Contact Person Name
Giovanni Salati
Contact Person Email
Giovanni.Salati@ausl.re.it
Site Name
Fondazione IRCCS San Gerardo Dei Tintori
Department Name
Emergenza Urgenza - Anestesia e Rianimazione
Contact Person Name
Giuseppe Foti
Contact Person Email
giu.foti@irccs-sangerardo.it
Site Name
Azienda Sanitaria Universitaria Giuliano Isontina
Department Name
Anestesia e Rianimazione
Contact Person Name
Erik Roman Pognuz
Contact Person Email
romanpognuz.erik@gmail.com

Sponsor

Primary sponsor

Full Name
Istituto Di Ricerche Farmacologiche Mario Negri
Organisation Type
Laboratory/Research/Testing facility
Country Of Registered Address
Italy

Third parties

  • {"country":"Italy","full_name":"Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico","duties_or_roles":"sponsorDuties code: 2","organisation_type":"Hospital/Clinic/Other health care facility"}

Investigational products

Investigational Product Name
Argon/Oxygen mixture
Active Substance
Argon; Oxygen
Modality
Small molecule
Routes Of Administration
Inhalation (gas)
Route
INHALATION GAS
Starting Dose
Ar 70% / O2 30% ventilation for 4 hours
Dose Levels
70% Ar / 30% O2 (single 4-hour exposure)
Frequency
Single 4-hour treatment (administration immediately post-ROSC)
Maximum Dose
70% (Ar)
Investigational Product Name
OXYGEN
Active Substance
Nitrous oxide; Oxygen
Modality
Small molecule
Routes Of Administration
Inhalation (gas)
Route
INHALATION GAS
Starting Dose
Ventilation with FiO2 of 30% (standard Air/O2) for 4 hours
Dose Levels
30% O2 (FiO2 30%) for 4 hours
Frequency
Continuous ventilation for 4 hours
Maximum Dose
30% (O2)

Related trials

Other published trials that may interest you.